A Greek registry of current type 2 diabetes management, aiming to determine core clinical approaches, patterns and strategies
Authors:
- AGREEMENT InvestigatorsAIAGREEMENT Investigators
- Stavros LiatisSLStavros Liatis
- Styliani IraklianouSIStyliani Iraklianou
- Kyriakos KazakosKKKyriakos Kazakos
- George MastorakosGMGeorge Mastorakos
- Kostas MiliosKMKostas Milios
- Zadalla MouslechZMZadalla Mouslech
- Marina NoutsouMNMarina Noutsou
- Emmanouil PagkalosEPEmmanouil Pagkalos
- Christos SampanisCSChristos Sampanis
Open Access
- 25 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 19 (1) , 39
Abstract
To analyze data in terms of the glycaemic control and therapeutic regimens used for Type-2 Diabetes Mellitus (T2DM) management in Greece, identify factors that influence clinical decisions and determine the level of compliance of T2DM management with the latest international and local guidelines. ‘AGREEMENT’ was a national-multicenter, non-interventional, cross-sectional disease registry. A total of 1191 adult T2DM patients were enrolled consecutively from 59 sites of the National Health System (NHS) or University Hospitals, representing the majority of Diabetes centers or Diabetes outpatient clinics in Greece with a broad geographic distribution. Patients were stratified by gender and analysis was done according to 3 treatment strategies: A (lifestyle changes or use of one oral antidiabetic agent), B (up to 3 antidiabetic agents including injectables but not insulin) and C (any regimens with insulin). Mean (±SD) HbA1c % of the total population was 7.1 (±1.2) while mean (±SD) FPG (mg/dl) was measured at 136 (±42). The proportion of patients who achieved HbA1c < 7% was 53% and ranged from 74.2% for group A, to 60.6% for group B and 35.5% for group C. Median age of the studied population was 65.0 year old (Interquartile Range-IQR 14.0) with an equal distribution of genders between groups. Patients on insulin therapy (treatment strategy C) were older (median age: 67 years vs 63 or 65 for A and B, respectively) with longer diabetes duration (mean duration: 15.3 years vs 5.2 and 10.1 for A and B, respectively). Patients who received insulin presented poor compliance. There was a consensus for a series of decision criteria and factors that potentially influence clinical decisions, used by physicians for selection of the therapeutic strategy among the three groups. Compliance with international and Greek guidelines received a high score among groups A, B and C. No significant differences were presented as per sites’ geographic areas, NHS or University centers and physicians’ specialty (endocrinologists, diabetologists and internists). The presented findings suggest the need for improvement of the glycaemic control rate, especially among insulin treated patients as this group seems to achieve low glycaemic control, by setting appropriate HbA1c targets along with timely and individualised intensification of treatment as well as post-therapy evaluation of the compliance with the proposed treatment.Keywords
Funding Information
- Sanofi Greece
This publication has 22 references indexed in Scilit:
- Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetesVascular Health and Risk Management, 2013
- Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA studyClinical Endocrinology, 2012
- Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy studyDiabetic Medicine, 2012
- Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyEuropean Heart Journal, 2011
- The importance of titrating starting insulin regimens in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2009
- Antihyperglycaemic treatment of type 2 diabetes: results from a national diabetes registerDiabetes & Metabolism, 2007
- Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: A retrospective database studyClinical Therapeutics, 2007
- Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002Clinical Therapeutics, 2006
- Global and societal implications of the diabetes epidemicNature, 2001
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998